Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Generalized Anxiety Disorder

ClinicalTrials.gov lists 507 trials for Generalized Anxiety Disorder or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 12.

MeSH D000098647 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 15 Phase 1/2 Phase 1/2 6 Phase 2 Phase 2 38 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 64 Phase 4 Phase 4 40 Not applicable Not applicable 275 Observational Observational 62 Phase 1 Phase 1 15 Phase 1/2 Phase 1/2 6 Phase 2 Phase 2 38 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 64 Phase 4 Phase 4 40 Not applicable Not applicable 275 Observational Observational 62

Trials per phase (log scale)

1 more section with rows

507 of the 507 trials are tagged with Generalized Anxiety Disorder itself; the rest are tagged with a narrower condition beneath it.

Get the Generalized Anxiety Disorder report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Generalized Anxiety Disorder trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 45

1991: 1 trials (Not applicable 1) 1996: 2 trials (Phase 3 1, Phase 1 1) 1998: 1 trials (Not applicable 1) 2000: 4 trials (Not applicable 1, Phase 4 1, Phase 2/3 1, Phase 2 1) 2001: 1 trials (Phase 3 1) 2002: 4 trials (Phase 2/3 1, Phase 2 2, Phase 1 1) 2003: 8 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 1) 2004: 11 trials (Observational 1, Not applicable 1, Phase 4 3, Phase 3 4, Phase 2 2) 2005: 12 trials (Phase 4 8, Phase 3 2, Phase 2 2) 2006: 19 trials (Observational 2, Not applicable 1, Phase 4 4, Phase 3 11, Phase 2 1) 2007: 17 trials (Observational 2, Not applicable 9, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 1/2 1, Phase 1 1) 2008: 31 trials (Observational 1, Not applicable 6, Phase 4 4, Phase 3 13, Phase 2 6, Phase 1 1) 2009: 13 trials (Observational 1, Not applicable 5, Phase 4 3, Phase 3 1, Phase 1 3) 2010: 13 trials (Observational 2, Not applicable 6, Phase 4 3, Phase 3 1, Phase 2/3 1) 2011: 8 trials (Observational 1, Not applicable 4, Phase 3 1, Phase 2 1, Phase 1/2 1) 2012: 14 trials (Observational 1, Not applicable 7, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2013: 15 trials (Observational 1, Not applicable 11, Phase 4 1, Phase 3 2) 2014: 15 trials (Observational 1, Not applicable 10, Phase 4 2, Phase 2 1, Phase 1/2 1) 2015: 11 trials (Observational 1, Not applicable 7, Phase 4 2, Phase 3 1) 2016: 22 trials (Observational 2, Not applicable 19, Phase 2 1) 2017: 16 trials (Observational 2, Not applicable 11, Phase 3 1, Phase 1/2 2) 2018: 25 trials (Observational 1, Not applicable 20, Phase 4 1, Phase 2 2, Phase 1 1) 2019: 17 trials (Observational 1, Not applicable 12, Phase 4 2, Phase 3 1, Phase 2 1) 2020: 28 trials (Observational 10, Not applicable 14, Phase 4 1, Phase 3 2, Phase 1 1) 2021: 24 trials (Observational 2, Not applicable 17, Phase 3 3, Phase 2 2) 2022: 27 trials (Observational 4, Not applicable 20, Phase 2 2, Phase 1 1) 2023: 27 trials (Observational 3, Not applicable 16, Phase 3 4, Phase 2/3 1, Phase 2 1, Phase 1 2) 2024: 32 trials (Observational 4, Not applicable 21, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1 1) 2025: 45 trials (Observational 10, Not applicable 27, Phase 3 3, Phase 2 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 42
2025 45
2024 32
2023 27
2022 27
2021 24
2020 28
2019 17
2018 25
2017 16

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 53 trials starting in 2026 and about 47 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 57 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 312 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Generalized Anxiety Disorder trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 15
Phase 1/2 6
Phase 2 38
Phase 2/3 6
Phase 3 64
Phase 4 40
Not applicable 275
Observational 62
Expanded access 1

How many Generalized Anxiety Disorder trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 33
Recruiting 75
Enrolling by invitation 5
Active, not recruiting 21
Completed 288

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Generalized Anxiety Disorder trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 12
AstraZeneca 9
Otsuka Pharmaceutical Development & Commercialization, Inc. 6
AbbVie 5

Which drugs are being tested for Generalized Anxiety Disorder? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PD 0332334 10
Duloxetine 6
Vortioxetine 5
CBT 4
Lorazepam 4

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IR (Immediate-Release) quetiapine fumarate (drug) 15
Treatment As Usual 14
Escitalopram Pill 11
Paroxetine IR 8
Sertralin 6

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Generalized Anxiety Disorder trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion spontaneous 3 2
Pneumonia 3 3
worsening depression 3 1
APPENDICITIS 2 1
Abdominal hernia 2 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Generalized Anxiety Disorder? (10)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA 2025 Yes
Efficacy of a Smartphone-Based Digital Therapeutic (Anzeilax) in Generalized Anxiety Disorder: Randomized Controlled Trial. Journal of medical Internet research 2025 Yes
Dietary counseling plus omega-3 supplementation in the treatment of generalized anxiety disorder: results of a randomized wait-list controlled pilot trial (the 'EASe-GAD Trial'). Nutritional neuroscience 2025 No
Prediction of generalized anxiety disorder treatment outcomes with neurobehavioral responses to approach-avoidance conflict: a randomized clinical trial. Translational psychiatry 2025 No
Cerina-Cognitive Behavioral Therapy-Based Mobile App for Managing Generalized Anxiety Disorder Symptoms Among University Students: Results From a Pilot Feasibility Randomized Controlled Trial. JMIR mHealth and uHealth 2025 No

Showing 5 of 10 publications.

Start your 14-day trial Email me all 10 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages